Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors

References

• Cancer in Norway 2012 – Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2014.
   Google Scholar
• Aziz NM. Cancer survivorship research: state of knowledge, challenges and opportunities. Acta Oncol. 2007;46:417–432.
   PubMed Web of Science ®Google Scholar
• Haugnes HS, Bosl GJ, Boer H, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol. 2012;30:3752–3763.
   PubMed Web of Science ®Google Scholar
• Haugnes HS, Stenklev NC, Brydoy M, et al. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study. Acta Oncol. 2018[cited 2018 Jan 31]; [9 p.]. DOI:10.1080/0284186X.2018.1433323
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol. 2007;25:708–714.
   PubMed Web of Science ®Google Scholar
• Gietema JA, Meinardi MT, Messerschmidt J, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet. 2000;355:1075–1076.
   PubMed Web of Science ®Google Scholar
• Hjelle LV, Gundersen PO, Oldenburg J, et al. Long-term Platinum retention after platinum-based chemotherapy in testicular cancer survivors: a 20-year follow-up study. Anticancer Res. 2015;35:1619–1625.
   PubMed Web of Science ®Google Scholar
• Sprauten M, Darrah TH, Peterson DR, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. J Clin Oncol. 2012;30:300–307.
   PubMed Web of Science ®Google Scholar
• Hohnloser JH, Schierl R, Hasford B, et al. Cisplatin based chemotherapy in testicular cancer patients: long term platinum excretion and clinical effects. Eur J Med Res. 1996;1:509–514.
   PubMedGoogle Scholar
• Brouwers EE, Huitema AD, Beijnen JH, et al. Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol. 2008;8:7.
   PubMedGoogle Scholar
• Schierl R, Rohrer B, Hohnloser J. Long-term platinum excretion in patients treated with cisplatin. Cancer Chemother Pharmacol. 1995;36:75–78.
   PubMed Web of Science ®Google Scholar
• Gelevert T, Messerschmidt J, Meinardi MT, et al. Adsorptive voltametry to determine platinum levels in plasma from testicular cancer patients treated with cisplatin. Ther Drug Monit. 2001;23:169–173.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Kraggerud SM, Brydoy M, et al. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med. 2007;5:70.
   PubMed Web of Science ®Google Scholar
• Boer H, Proost JH, Nuver J, et al. Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors. Ann Oncol. 2015;26:2305–2310.
   PubMed Web of Science ®Google Scholar
• Brydoy M, Oldenburg J, Klepp O, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst. 2009;101:1682–1695.
   PubMedGoogle Scholar
• Peckham MJ, McElwain TJ, Barrett A, et al. Combined management of malignant teratoma of the testis. Lancet. 1979;2:267–270.
   PubMed Web of Science ®Google Scholar
• Brydoy M, Fossa SD, Klepp O, et al. Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol. 2010;58:134–140.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Behrens BC, Ostchega Y, et al. High dose cisplatin and high dose carboplatin in refractory ovarian cancer. Cancer Treat Rev. 1985;12:59–65.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Fossa SD, Dahl AA. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res. 2006;15:791–800.
   PubMed Web of Science ®Google Scholar
• Thorsen L, Nystad W, Dahl O, et al. The level of physical activity in long-term survivors of testicular cancer. Eur J Cancer. 2003;39:1216–1221.
   PubMed Web of Science ®Google Scholar
• Hjelle LV, Bremnes RM, Gundersen PO, et al. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors. Urol Oncol. 2016;34:487.e13–e20.
   PubMed Web of Science ®Google Scholar
• Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165:710–718.
   PubMed Web of Science ®Google Scholar
• Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ. 1995;310:170.
   PubMed Web of Science ®Google Scholar
• Bender R, Lange S. Adjusting for multiple testing–when and how? J Clin Epidemiol. 2001;54:343–349.
   PubMed Web of Science ®Google Scholar
• Dikhoff TGMH, Goeij JJM, Mcvie JG. Long-term body retention and tissue distribution of platinum in cisplatin treated cancer patients. J Radioanal Nucl Chem. 1998;236:81–86.
   Web of Science ®Google Scholar
• Caroli S, Alimonti A, Petrucci F, et al. Assessment of exposure to platinum-group metals in urban children. Spectrochim Acta B. 2001;56:1241–1248.
   Web of Science ®Google Scholar
• Morton O, Puchelt H, Hernández E, et al. Traffic-related platinum group elements (PGE) in soils from Mexico City. J Geochem Explor. 2001;72:223–227.
   Web of Science ®Google Scholar
• Pawlak J, Lodyga-Chruscinska E, Chrustowicz J. Fate of platinum metals in the environment. J Trace Elem Med Biol. 2014;28:247–254.
   PubMed Web of Science ®Google Scholar
• Barbante C, Veysseyre A, Ferrari C, et al. Greenland snow evidence of large scale atmospheric contamination for platinum, palladium, and rhodium. Environ Sci Technol. 2001;35:835–839.
   PubMed Web of Science ®Google Scholar
• Wiseman CLS. Platinum metals in airborne particulate matter and their bioaccessibility. In: Zereini F, Wiseman CLS, editors. Platinum metals in the environment. Berlin, Heidelberg: Springer Berlin Heidelberg; 2015. p. 447–462.
   Google Scholar
• IARC Monographs [Internet]. Lyon, France:International Agency for Research on Cancer;1987. Available from: http://monographs.iarc.fr/ENG/Monographs/suppl7/Suppl7-53.pdf.
   Google Scholar
• Kier MG, Hansen MK, Lauritsen J, et al. Second malignant neoplasms and cause of death in patients with germ cell cancer: a Danish Nationwide Cohort Study. JAMA Oncol. 2016;2:1624–1627.
   PubMed Web of Science ®Google Scholar
• Fung C, Fossa SD, Milano MT, et al. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol. 2013;31:3807–3814.
   PubMed Web of Science ®Google Scholar
• Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97:1354–1365.
   PubMed Web of Science ®Google Scholar
• Lauritsen J, Mortensen MS, Kier MG, et al. Renal impairment and late toxicity in germ-cell cancer survivors. Ann Oncol. 2015;26:173–178.
   PubMed Web of Science ®Google Scholar
• Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14:iv45–iv54.
   PubMed Web of Science ®Google Scholar
• Krarup-Hansen A, Rietz B, Krarup C, et al. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropathol Appl Neurobiol. 1999;25:29–40.
   PubMed Web of Science ®Google Scholar
• Breglio AM, Rusheen AE, Shide ED, et al. Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun. 2017;8:1654.
   PubMed Web of Science ®Google Scholar
• Chang Q, Ornatsky OI, Siddiqui I, et al. Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive collagen binding in tumor and normal tissues. Sci Rep. 2016;6:36641.
   PubMed Web of Science ®Google Scholar
• Hu H, Rabinowitz M, Smith D. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect. 1998;106:1.
   PubMed Web of Science ®Google Scholar
• Islami F, Moreira DM, Boffetta P, et al. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol. 2014;66:1054–1064.
   PubMed Web of Science ®Google Scholar
• Bjerkaas E, Parajuli R, Weiderpass E, et al. Smoking duration before first childbirth: an emerging risk factor for breast cancer? Results from 302,865 Norwegian women. Cancer Causes Control. 2013;24:1347–1356.
   PubMed Web of Science ®Google Scholar
• Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol. 2012;23:1880–1888.
   PubMed Web of Science ®Google Scholar
• Garner R, Kumari R, Lanyon P, et al. Prevalence, risk factors and associations of primary Raynaud’s phenomenon: systematic review and meta-analysis of observational studies. BMJ Open. 2015;5:e006389.
   PubMed Web of Science ®Google Scholar